42O Biomarker analysis from KAITLIN, a randomised phase III study of adjuvant trastuzumab emtansine (TDM-1; K) plus pertuzumab (P) versus trastuzumab (H) plus taxane (T) plus P after anthracyclines (AC) for high-risk HER2-positive early breast cancer (EBC)
Titel:
42O Biomarker analysis from KAITLIN, a randomised phase III study of adjuvant trastuzumab emtansine (TDM-1; K) plus pertuzumab (P) versus trastuzumab (H) plus taxane (T) plus P after anthracyclines (AC) for high-risk HER2-positive early breast cancer (EBC)
Auteur:
Metzger, O. Lambertini, C. Krop, I.E. Lewis Phillips, G. Perou, C.M. Symmans, F. Melero, I. Harbeck, N. Winer, E.P. Im, S-A. Barrios, C.H. Bonnefoi, H. Gralow, J.R. Ellis, P.A. Gianni, L. Toi, M. Swain, S.M. Boulet, T. Song, C. de Haas, S.